The new class of drugs - DFSAs - permanently bind to the enzyme, blocking its action and stopping it from spreading further, the journal Science reported.
These work by binding chemically to that enzyme's active site to inhibit its action. (Protease cuts the raw chain of virus protein produced by a subverted cell into functional molecules.) However, the mechanism is not quite identical.
Scientists aren't exactly sure why the Cox-2s could fight cancer, although it appears much of their action lies in the inhibition of the Cox-2 enzyme, which is also involved in swelling.